Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2024 Earnings Conference Call July 29, 2024 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charles Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President of Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann & Co. David Amsellem - Piper Sandler & Co. Swayampakula Ramakanth - H.C. Wainwright Joon Lee - Truist Operator Hello.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.25 per share a year ago.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
